help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kolterman, O. G.
Right arrow Articles by Baron, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kolterman, O. G.
Right arrow Articles by Baron, A. D.
The Journal of Clinical Endocrinology & Metabolism Vol. 88, No. 7 3082-3089
Copyright © 2003 by The Endocrine Society

Synthetic Exendin-4 (Exenatide) Significantly Reduces Postprandial and Fasting Plasma Glucose in Subjects with Type 2 Diabetes

Orville G. Kolterman, John B. Buse, Mark S. Fineman, Eling Gaines, Sonja Heintz, Thomas A. Bicsak, Kristin Taylor, Dennis Kim, Maria Aisporna, Yan Wang and Alain D. Baron

Amylin Pharmaceuticals, Inc. (O.G.K., M.S.F., E.G., S.H., T.A.B., K.T., D.K., M.A., Y.W., A.D.B.), San Diego, California 92121; and University of North Carolina School of Medicine (J.B.B.), Chapel Hill, North Carolina 27599

Address all correspondence and requests for reprints to: Alain D. Baron, M.D., Amylin Pharmaceuticals, Inc., 9373 Towne Centre Drive, San Diego, California 92121. E-mail: abaron{at}amylin.com.

Despite the advent of new treatments, glucose control in the type 2 diabetes population is unsatisfactory. AC2993 (synthetic exendin-4; exenatide), a novel glucose-dependent insulinotropic agent, exhibited notable antidiabetic potential in two clinical studies in patients with type 2 diabetes. In study A, 24 subjects received sc injections of study medication (0.1 µg/kg AC2993 or placebo) twice daily with meals for 5 d. Statistically significant reductions in mean postprandial circulating concentrations of glucose, insulin, and glucagon occurred following treatment with AC2993. In study B, 13 subjects receiving a single dose of study medication (0.05, 0.1, or 0.2 µg/kg AC2993 or placebo) following an overnight fast had reduced fasting plasma glucose concentrations during the subsequent 8-h period. The relative glucose and insulin concentration profiles were consistent with glucose-dependent insulinotropism. AC2993 was well tolerated. Mild transient headache, nausea, and vomiting were the main adverse events. In conclusion, AC2993 acutely and markedly reduces fasting and postprandial glucose concentrations in patients with type 2 diabetes. During fasting, glucose-dependent enhancement of insulin secretion and suppression of glucagon secretion are the predominant mechanisms, and postprandially, slowing of gastric emptying is additionally operative. This robust antidiabetic effect warrants further evaluation of AC2993.

This work was supported by Amylin Pharmaceuticals, Inc. (San Diego, CA).

Abbreviations: AUC, Area under the curve; BID, administered twice daily; GLP-1, glucagon-like peptide-1; HbA1c, hemoglobin A1c; OAA, oral antidiabetic agent.




This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
B. Laferrere, J. Teixeira, J. McGinty, H. Tran, J. R. Egger, A. Colarusso, B. Kovack, B. Bawa, N. Koshy, H. Lee, et al.
Effect of Weight Loss by Gastric Bypass Surgery Versus Hypocaloric Diet on Glucose and Incretin Levels in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2479 - 2485.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
L. F Van Gaal, S. W Gutkin, and M. A Nauck
Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?
Eur. J. Endocrinol., June 1, 2008; 158(6): 773 - 784.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
M. Salehi, B. A. Aulinger, and D. A. D'Alessio
Targeting {beta}-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Endocr. Rev., May 1, 2008; 29(3): 367 - 379.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
E. Muscelli, A. Mari, A. Casolaro, S. Camastra, G. Seghieri, A. Gastaldelli, J. J. Holst, and E. Ferrannini
Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients
Diabetes, May 1, 2008; 57(5): 1340 - 1348.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
C. L. Martin
Beyond Glycemic Control: The Effects of Incretin Hormones in Type 2 Diabetes
The Diabetes Educator, May 1, 2008; 34(Supplement_3): 66S - 72S.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
M. S. Winzell and B. Ahren
Durable islet effects on insulin secretion and protein kinase A expression following exendin-4 treatment of high-fat diet-fed mice
J. Mol. Endocrinol., February 1, 2008; 40(2): 93 - 100.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
A. Mari, W. A. Scherbaum, P. M. Nilsson, G. Lalanne, A. Schweizer, B. E. Dunning, S. Jauffret, and J. E. Foley
Characterization of the Influence of Vildagliptin on Model-Assessed -Cell Function in Patients with Type 2 Diabetes and Mild Hyperglycemia
J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 103 - 109.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
N. A. Sherry, W. Chen, J. A. Kushner, M. Glandt, Q. Tang, S. Tsai, P. Santamaria, J. A. Bluestone, A.-M. B. Brillantes, and K. C. Herold
Exendin-4 Improves Reversal of Diabetes in NOD Mice Treated with Anti-CD3 Monoclonal Antibody by Enhancing Recovery of {beta}-Cells
Endocrinology, November 1, 2007; 148(11): 5136 - 5144.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. Kim, L. MacConell, D. Zhuang, P. A. Kothare, M. Trautmann, M. Fineman, and K. Taylor
Effects of Once-Weekly Dosing of a Long-Acting Release Formulation of Exenatide on Glucose Control and Body Weight in Subjects With Type 2 Diabetes
Diabetes Care, June 1, 2007; 30(6): 1487 - 1493.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
B. E. Dunning and J. E. Gerich
The Role of {alpha}-Cell Dysregulation in Fasting and Postprandial Hyperglycemia in Type 2 Diabetes and Therapeutic Implications
Endocr. Rev., May 1, 2007; 28(3): 253 - 283.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
S. T. Haines
Emerging Treatments for Patients With Type 2 Diabetes
The Diabetes Educator, May 1, 2007; 33(Supplement_5): 105S - 110S.
[Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
B. Zinman, B. J. Hoogwerf, S. Duran Garcia, D. R. Milton, J. M. Giaconia, D. D. Kim, M. E. Trautmann, and R. G. Brodows
The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes: A Randomized Trial
Ann Intern Med, April 3, 2007; 146(7): 477 - 485.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
T. H Claus, C. Q Pan, J. M Buxton, L. Yang, J. C Reynolds, N. Barucci, M. Burns, A. A Ortiz, S. Roczniak, J. N Livingston, et al.
Dual-acting peptide with prolonged glucagon-like peptide-1 receptor agonist and glucagon receptor antagonist activity for the treatment of type 2 diabetes
J. Endocrinol., February 1, 2007; 192(2): 371 - 380.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
K. G. Murphy, W. S. Dhillo, and S. R. Bloom
Gut Peptides in the Regulation of Food Intake and Energy Homeostasis
Endocr. Rev., December 1, 2006; 27(7): 719 - 727.
[Abstract] [Full Text] [PDF]

Home page
 J Am Board Fam MedHome page
D. Hinnen, L. L. Nielsen, A. Waninger, and P. Kushner
Incretin Mimetics and DPP-IV Inhibitors: New Paradigms for the Treatment of Type 2 Diabetes
J Am Board Fam Med, November 1, 2006; 19(6): 612 - 620.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
D. Soon, P. A. Kothare, H. Linnebjerg, S. Park, E. Yuen, K. F. Mace, and S. D. Wise
Effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy asian men.
J. Clin. Pharmacol., October 1, 2006; 46(10): 1179 - 1187.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
B. K. Yoo, D. M. Triller, and D. J. Yoo
Exenatide: A New Option for the Treatment of Type 2 Diabetes
Ann. Pharmacother., October 1, 2006; 40(10): 1777 - 1784.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. D. Wideman, I. L. Y. Yu, T. D. Webber, C. B. Verchere, J. D. Johnson, A. T. Cheung, and T. J. Kieffer
Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1)
PNAS, September 5, 2006; 103(36): 13468 - 13473.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
L. L. Baggio, D. Holland, J. Wither, and D. J. Drucker
Lymphocytic Infiltration and Immune Activation in Metallothionein Promoter-Exendin-4 (MT-Exendin) Transgenic Mice
Diabetes, June 1, 2006; 55(6): 1562 - 1570.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
P. D. van Poelje, S. C. Potter, V. C. Chandramouli, B. R. Landau, Q. Dang, and M. D. Erion
Inhibition of Fructose 1,6-Bisphosphatase Reduces Excessive Endogenous Glucose Production and Attenuates Hyperglycemia in Zucker Diabetic Fatty Rats
Diabetes, June 1, 2006; 55(6): 1747 - 1754.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Park, X. Dong, T. L. Fisher, S. Dunn, A. K. Omer, G. Weir, and M. F. White
Exendin-4 Uses Irs2 Signaling to Mediate Pancreatic beta Cell Growth and Function
J. Biol. Chem., January 13, 2006; 281(2): 1159 - 1168.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
L Marenah, P R Flatt, D F Orr, C Shaw, and Y H A Abdel-Wahab
Skin secretions of Rana saharica frogs reveal antimicrobial peptides esculentins-1 and -1B and brevinins-1E and -2EC with novel insulin releasing activity
J. Endocrinol., January 1, 2006; 188(1): 1 - 9.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
N. N. Zammitt and B. M. Frier
Hypoglycemia in Type 2 Diabetes: Pathophysiology, frequency, and effects of different treatment modalities
Diabetes Care, December 1, 2005; 28(12): 2948 - 2961.
[Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
F. Fehse, M. Trautmann, J. J. Holst, A. E. Halseth, N. Nanayakkara, L. L. Nielsen, M. S. Fineman, D. D. Kim, and M. A. Nauck
Exenatide Augments First- and Second-Phase Insulin Secretion in Response to Intravenous Glucose in Subjects with Type 2 Diabetes
J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 5991 - 5997.
[Abstract] [Full Text] [PDF]

Home page
 PhysiologyHome page
E. M Sinclair and D. J. Drucker
Proglucagon-Derived Peptides: Mechanisms of Action and Therapeutic Potential
Physiology, October 1, 2005; 20(5): 357 - 365.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
T. Talsania, Y. Anini, S. Siu, D. J. Drucker, and P. L. Brubaker
Peripheral Exendin-4 and Peptide YY3-36 Synergistically Reduce Food Intake through Different Mechanisms in Mice
Endocrinology, September 1, 2005; 146(9): 3748 - 3756.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
P. A. Kothare, D. K. W. Soon, H. Linnebjerg, S. Park, C. Chan, A. Yeo, M. Lim, K. F. Mace, and S. D. Wise
Effect of Exenatide on the Steady-State Pharmacokinetics of Digoxin
J. Clin. Pharmacol., September 1, 2005; 45(9): 1032 - 1037.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
A. Aziz, G. H. Anderson, A. Giacca, and F. Cho
Hyperglycemia after protein ingestion concurrent with injection of a GLP-1 receptor agonist in rats: a possible role for dietary peptides
Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2005; 289(3): R688 - R694.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. M. Kendall, M. C. Riddle, J. Rosenstock, D. Zhuang, D. D. Kim, M. S. Fineman, and A. D. Baron
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea
Diabetes Care, May 1, 2005; 28(5): 1083 - 1091.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. A. DeFronzo, R. E. Ratner, J. Han, D. D. Kim, M. S. Fineman, and A. D. Baron
Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes
Diabetes Care, May 1, 2005; 28(5): 1092 - 1100.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
E. Blase, K. Taylor, H.-y. Gao, M. Wintle, and M. Fineman
Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times in Relation to Subcutaneous Injection of Exenatide (Exendin-4) in Healthy Subjects
J. Clin. Pharmacol., May 1, 2005; 45(5): 570 - 577.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
K. Dungan and J. B. Buse
Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide
Clin. Diabetes, April 1, 2005; 23(2): 56 - 62.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
B. R. Gedulin, S. E. Nikoulina, P. A. Smith, G. Gedulin, L. L. Nielsen, A. D. Baron, D. G. Parkes, and A. A. Young
Exenatide (Exendin-4) Improves Insulin Sensitivity and {beta}-Cell Mass in Insulin-Resistant Obese fa/fa Zucker Rats Independent of Glycemia and Body Weight
Endocrinology, April 1, 2005; 146(4): 2069 - 2076.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
O. G. Kolterman, D. D. Kim, L. Shen, J. A. Ruggles, L. L. Nielsen, M. S. Fineman, and A. D. Baron
Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus
Am. J. Health Syst. Pharm., January 15, 2005; 62(2): 173 - 181.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
S. V Joy, P. T Rodgers, and A. C Scates
Incretin Mimetics as Emerging Treatments for Type 2 Diabetes
Ann. Pharmacother., January 1, 2005; 39(1): 110 - 118.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. B. Buse, R. R. Henry, J. Han, D. D. Kim, M. S. Fineman, A. D. Baron, and for the Exenatide-113 Clinical Study Group
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 Diabetes
Diabetes Care, November 1, 2004; 27(11): 2628 - 2635.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
Gut-Derived Incretin Hormones and New Therapeutic Approaches
Diabetes Care, October 1, 2004; 27(10): 2554 - 2559.
[Full Text] [PDF]

Home page
 DiabetesHome page
C. F. Deacon
Therapeutic Strategies Based on Glucagon-Like Peptide 1
Diabetes, September 1, 2004; 53(9): 2181 - 2189.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
K. B. Degn, B. Brock, C. B. Juhl, C. B. Djurhuus, J. Grubert, D. Kim, J. Han, K. Taylor, M. Fineman, and O. Schmitz
Effect of Intravenous Infusion of Exenatide (Synthetic Exendin-4) on Glucose-Dependent Insulin Secretion and Counterregulation During Hypoglycemia
Diabetes, September 1, 2004; 53(9): 2397 - 2403.
[Abstract] [Full Text] [PDF]

Home page
 JRSMHome page
C M. B Edwards
GLP-1: target for a new class of antidiabetic agents?
J R Soc Med, June 1, 2004; 97(6): 270 - 274.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
D. A. D'Alessio and T. P. Vahl
Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes
Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E882 - E890.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2003 by The Endocrine Society